What Are The Possible Side Effects Of Insulin Lispro (humalog, Humalog Cartridge, Humalog Kwikpen, Humalog Pen)?
HUMALOG (insulin lispro) Injection DESCRIPTION HUMALOG® (insulin lispro injection) is a rapid-acting human insulin analog used to lower blood glucose. Insulin lispro is produced by recombinant DNA technology utilizing a non-pathogenic laboratory strain of Escherichia coli. Insulin lispro differs from human insulin in that the amino acid proline at position B28 is replaced by lysine and the lysine in position B29 is replaced by proline. Chemically, it is Lys(B28), Pro(B29) human insulin analog and has the empirical formula C257H383N65O77S6 and a molecular weight of 5808, both identical to that of human insulin. HUMALOG has the following primary structure: HUMALOG is a sterile, aqueous, clear, and colorless solution. Each milliliter of HUMALOG U-100 contains insulin lispro 100 units, 16 mg glycerin, 1.88 mg dibasic sodium phosphate, 3.15 mg Metacresol, zinc oxide content adjusted to provide 0.0197 mg zinc ion, trace amounts of phenol, and Water for Injection. Insulin lispro has a pH of 7.0 to 7.8. The pH is adjusted by addition of aqueous solutions of hydrochloric acid 10% and/or sodium hydroxide 10%. Each milliliter of HUMALOG U-200 contains insulin lispro 200 units, 16 mg glycerin, 5 mg tromethamine, 3.15 mg Metacresol, zinc oxide content adjusted to provide 0.046 mg zinc ion, trace amounts of phenol, and Water for Injection. Insulin lispro has a pH of 7.0 to 7.8. The pH is adjusted by addition of aqueous solutions of hydrochloric acid 10% and/or sodium hydroxide 10%. font size A A A 1 2 3 4 5 Next What is Type 2 Diabetes? The most common form of diabetes is type 2 diabetes, formerly called non-insulin dependent diabetes mellitus or "adult onset" diabetes, so-called because it typically develops in adults over age 35, though it can develop at any age. Type 2 diabetes i Continue reading >>
HUMALOGïƒ¢ Marketed PI_v10.0_2Nov15 Page 1 of 12 HUMALOG Â® [insulin lispro (rbe)] HUMALOG Â® MIX25 (25% insulin lispro (rbe) and 75% insulin lispro (rbe) protamine suspension) HUMALOG Â® MIX50 (50% insulin lispro (rbe) and 50% insulin lispro (rbe) protamine suspension) HUMALOG is a Lilly human insulin analogue. It differs from other insulins because it has a unique structure, a very quick onset of action and a shorter duration of activity. HUMALOG MIX25 and HUMALOG MIX50 combine the quick onset of action of HUMALOG with an extended duration of activity attributable to the intermediate acting component of the mixture. HUMALOG, HUMALOG MIX25 and HUMALOG MIX50 should be given immediately (up to 15 minutes) before a meal. When necessary, HUMALOG can be given soon after meals (within 20 minutes of the start of a meal). The safety and efficacy of HUMALOG MIX25 and HUMALOG MIX50 given after a meal has not been established. NAME OF DRUG Insulin lispro (rbe) DESCRIPTION The HUMALOG range consists of three presentations: HUMALOG - Insulin lispro solution [recombinant DNA origin] is an aqueous solution of insulin lispro ([Lys (B28), Pro (B29)] human insulin analogue, adjusted to pH 7.0 - 7.8. It also contains meta-Cresol, glycerol, dibasic sodium phosphate, zinc oxide and water for injection. Hydrochloric acid and sodium hydroxide may be used to adjust pH. HUMALOG is available as a clear, colourless solution for parenteral administration in a concentration of 100 units/mL in 10 mL vials, 3 mL cartridges and 3 mL prefilled insulin delivery devices (HUMALOG KwikPen). HUMALOG MIX25 â€“ 25% insulin lispro and 75% insulin lispro protamine suspension (NPL) [recombinant DNA origin] is a mixture of insulin lispro, a rapid-acting blood glucose lowering agent and insulin lisp Continue reading >>
Rapid-Acting Analogues Short-Acting Insulins Intermediate-Acting Insulins Long-Acting Insulins Combination Insulins Onset: 12 - 18 min Peak: 1-3 hours Duration: 3-5 hours Solution: Clear Comments: NovoLog should generally be given immediately before a meal (start of meal within 5-10 minutes after injection) because of its fast onset of action. NovoLog is homologous with regular human insulin with the exception of a single substitution of the amino acid proline by aspartic acid in position B28 (beta chain). Insulin lispro (Humalog) and insulin aspart (Novolog), when administered intravenously, show pharmacodynamic parameters similar to regular insulin. Mixing NPH: If NovoLog is mixed with NPH human insulin, NovoLog should be drawn into the syringe first. The injection should be made immediately after mixing. Regular insulin: Compatible - but NO support clinically for such a mixture. Draw up Novolog first before drawing up Regular Insulin. Mixtures should not be administered intravenously. When used in external subcutaneous infusion pumps for insulin, NovoLog should not be mixed with any other insulins or diluent. When rapid-acting insulin is mixed with either an intermediate- or long-acting insulin, the mixture should be injected within 15 min before a meal. INDICATIONS AND USAGE Treatment of Diabetes Mellitus NovoLog is an insulin analog indicated to improve glycemic control in adults and children with diabetes mellitus. DOSAGE AND ADMINISTRATION Dosing NovoLog is an insulin analog with an earlier onset of action than regular human insulin. The dosage of NovoLog must be individualized. NovoLog given by subcutaneous injection should generally be used in regimens with an intermediate or long-acting insulin [see package insert for Warnings and Precautions (5), How Supplied Continue reading >>
Humalog Vs. Novolog: What’s The Difference?
The two leaders in the fast acting insulin market, Humalog and Novolog, are the most common types of fast acting insulin used by those with diabetes today. Fast Acting, mealtime insulin is a type of insulin that is injected before or right after eating. When you eat your blood glucose begins to rise. Fast acting insulin, Humalog and Novolog work to help manage these rises or spikes to keep your blood glucose levels more within range and balanced. When you use a fast acting insulin like Humalog or Novolog, you typically will continue to take a long acting insulin to help manage your levels between your meals and throughout the night. The question is though, is there really a difference between the two? Endocrinologists and other medical professionals don’t seem to really think there is, stating the two are virtually interchangeable. But that’s not really the full story. Humalog (Insulin Lispro) Insulin Lispro (Humalog) has been on the market since 1996, when it was first introduced by Eli Lily. Humalog is the first insulin analogue that was used clinically. Insulin Lispro received its name due to its structure. The difference between it and regular insulin was the switch between the lysine B28 (an amino acid) and proline B29. The formula consists of a hexametric solution available in vials and pen form. After a subcutaneous injection, the formula converts into a monomeric formula which allows it to have a fast absorption in the body. The one noted negative factor of Humalog is its short term control of glucose levels. Additionally, if it is injected and mealtime happens to be delayed, a hypoglycemic episode may occur. For Humalog to be most effective it is to be injected 15 minutes prior to the start of a meal. I recommend reading the following articles: Humalog is a Continue reading >>
Similar Safety, Efficacy, Immunogenicity Shown For Admelog And Reference Humalog
Similar Safety, Efficacy, Immunogenicity Shown for Admelog and Reference Humalog SAR342434, or Admelog, a follow-on of insulin lispro (Humalog), showed similar efficacy, safety, and immunogenicity to its reference in patients with type 2 diabetes who also used insulin glargine (Lantus) as basal insulin, according to the results of the SORELLA-2 study, published in the January 2018 issue of Diabetes Technology & Therapeutics. SAR342434, or Admelog, a follow-on of insulin lispro (Humalog), showed similar efficacy, safety, and immunogenicity to its reference in patients with type 2 diabetes who also used insulin glargine (Lantus) as basal insulin, according to the results of the SORELLA-2 study, published in the January 2018 issue of Diabetes Technology & Therapeutics. Karl-Michael Derwahl, MD, PhD, and colleagues conclude that Admelog and Humalog, when used for 6 months in combination with Lantus, provide effective and similar glucose control in patients with type 2 diabetes. Admelog is sponsored by Sanofi, which funded the study. SORELLA-2 was a 6-month, randomized, open-label, multinational Phase 3 study in patients with diabetes who received multiple daily injections of Admelog (n = 253) or Humalog (n = 252) plus once-daily Lantus. Insulin doses were adjusted to achieve fasting and 2-hour postprandial glucose targets according to American Diabetes Association guidelines. The studys primary endpoint was the hemoglobin A1c (HbA1c) change from baseline to week 26; secondary endpoints included fasting plasma glucose (FPG), 7-point self-monitored plasma glucose (SMPG) profiles, hypoglycemic events, treatment emergent adverse events (TEAEs), and anti-insulin antibodies (AIA). Change in HbA1c from baseline to week 26 was similar in both treatment groups, as calculated by lea Continue reading >>
- Immunotherapy treatment shown safe in type 1 diabetes clinical trial
- Type 2 diabetes and obesity induce similar transcriptional reprogramming in human myocytes
- Mobile App-Based Interventions to Support Diabetes Self-Management: A Systematic Review of Randomized Controlled Trials to Identify Functions Associated with Glycemic Efficacy
Humalog Vs. Novolog: Important Differences And More
Humalog and Novolog are two diabetes medications. Humalog is the brand-name version of insulin lispro, and Novolog is the brand-name version of insulin aspart. These drugs both help control blood glucose (sugar) in people with type 1 and type 2 diabetes. Humalog and Novolog are both rapid acting. That means they work more quickly than other types of insulin. There are important distinctions between Humalog and Novolog, however, and the drugs are not directly interchangeable. Check out this comparison so you can work with your doctor to choose a drug that’s right for you. Insulin is injected under your skin fat. It’s the most common type of treatment for type 1 diabetes because it works quickly. It’s also the only type of diabetes medication that’s absorbed into the bloodstream. Humalog and Novolog are both equivalent to the insulin made in your body. Unlike oral diabetes drugs, insulin provides fast relief for changes in your blood sugar. The type of insulin your doctor prescribes depends on how often and how much your blood sugar fluctuates each day. The table below provides quick facts at a glance. Brand name Humalog Novolog What is the generic drug? insulin lispro insulin aspart Is a generic version available? no no What does it treat? type 1 and type 2 diabetes type 1 and type 2 diabetes What form does it come in? solution for injection solution for injection What strengths does it come in? • 3-mL cartridges • 3-mL prefilled KwikPen • 3-mL vials • 10-mL vials • 3-mL FlexPen • 3-mL FlexTouch • 3-mL PenFill cartridges • 10-mL vials What is the typical length of treatment? long-term long-term How do I store it? Refrigerate at 36° to 46°F (2° to 8°C). Do not freeze the drug. Refrigerate at 36° to 46°F (2° to 8°C). Do not freeze the drug. Continue reading >>
Admelog Vs Humalog | Admelog (insulin Lispro Injection) 100 Units/ml
Your colleague wants to share information about a new insulin lispro option Indication for ADMELOG (insulin lispro injection) 100 Units/mL ADMELOG is a rapid-acting human insulin analog indicated to improve glycemic control in adults with type 2 diabetes and adults and children (3 years and older) with type 1 diabetes. Important Safety Information for ADMELOG (insulin lispro injection) 100 Units/mL ADMELOG is contraindicated during episodes of hypoglycemia and in patients with hypersensitivity to insulin lispro or to any of its excipients. Insulin pens and needles must never be shared between patients, even if the needle is changed. Do NOT reuse needles. Monitor blood glucose in all patients treated with insulin. Modify insulin regimens cautiously and only under medical supervision. Changes in insulin strength, manufacturer, type, or method of administration may result in the need for a change in insulin dose or an adjustment in concomitant oral antidiabetic treatment. Changes in insulin regimen may result in hyperglycemia or hypoglycemia. Hypoglycemia is the most common adverse reaction associated with insulins, including ADMELOG, and may be life-threatening. Accidental mix-ups between basal insulin products and other insulins, particularly rapid-acting insulins, have been reported. To avoid medication errors between ADMELOG and other insulins, instruct patients to always check the insulin label before each injection. Severe, life-threatening, generalized allergy, including anaphylaxis, can occur with insulin products, including ADMELOG. If hypersensitivity reactions occur, discontinue ADMELOG, treat per standard of care and monitor until symptoms and signs resolve. All insulin products, including ADMELOG, can cause hypokalemia. Untreated hypokalemia may cause respira Continue reading >>
Why Is Humalog Expensive? And How Can You Save?
Humalog Vs. Novolog.
It wasn't until recently that I started thinking about building up a tolerance to insulin. Do you build up a chemical familiarity, a resistance of sorts, to a drug after taking it for ... oh, say a few decades? Do PWD eventually become the Dread Pirate Roberts, building up a tolerance to iocane powder? "I realize this is probably ridiculous, and I'm sure there aren't any studies on this," I said to my doctor the other week. "But it has prompted me to want to try a different kind of fast acting insulin, to see if I have better results. Is that something I'm able to do, to have a script written for a one-off in order to assess how the insulin might work for me?" "We can do that." And I left the appointment, expecting my pharmacy to auto-dial me when my order was complete. Instead, a three-month supply of Novolog ended up on my doorstep, having been accidentally shuttled through my mail order pharmacy and eating up my insurance order that was intended for my normal course of Humalog. Which is why I'm experimenting with Novolog for the next few months, as a result of a shipping error. I've been taking Humalog for over ten years, after switching from Regular insulin before starting on my insulin pump, so I feel like I'm familiar with how Humalog acts in my pump and on my blood sugars. Switching to a different, but similar, rapid-acting analog should hopefully be a seamless transition. Last night was my first pump-load of Novolog, despite the last unopened bottle of Humalog in my stash. (I didn't want to use up the Humalog entirely, then switch to Novolog, because if I absolutely hated the new insulin, I'd be stuck with it.) So far, last night was entirely uneventful, and the biggest change I've noticed (in less than 24 hours of use) is that the bottle of Novolog plays host t Continue reading >>
Humalog U-200 Kwikpen Could Cost Patients Less Than Humalog U-100 Kwikpen
Humalog U-200 KwikPen may be an effective option—from mealtime initiation through dosage increases—so fewer changes in therapy may be needed down the road* Patient preference (vs Humalog U-100 KwikPen) 9 out of 10 patients expressing a preference preferred Humalog U-200 KwikPen over Humalog U-100 KwikPen†1 In a single-visit, 2-period, crossover, simulated-use preference study, 101 patients compared U-100 KwikPen and U-200 KwikPen by injecting 15 units and 50 units into an injection pad to determine final preference (95% CI, 0.81-0.94; P<.0001). Afterwards, they completed 2 self-administered questionnaires (Insulin Device Assessment Battery and Insulin Device Preference Battery adapted for this study) to determine final preference.1 Bioequivalence—with half the volume Bioequivalent‡ to Humalog U-100 so you can expect a similar efficacy and safety profile. Plus, it delivers the same dose in half the liquid volume. Savings Available at the lowest brand co-pay for most patients,§ and could even cost less than Humalog U-100 KwikPen|| Option for patients who require >20 units of mealtime insulin/day. In a device preference study between U-200 KwikPen and U-100 KwikPen, 90/101 patients expressed a preference between the devices. As determined by area under the curve and maximum concentration. Source: Managed Markets Insight & Technology (MMIT), LLC as of 06/2017, and is subject to change without notice by a health plan or state. Please contact the plan or state for the most current information. “Patients” consists of all insured lives (Medicaid, Medicare, commercial insurance). See full terms and conditions on back of savings card. For eligible commercially insured patients. Continue reading >>
Comparison Of Insulin Aspart And Lispro: Pharmacokinetic And Metabolic Effects.
Abstract OBJECTIVE: To compare insulin levels and actions in patients with type 1 diabetes after subcutaneous injection of the rapid-acting insulin analogs aspart and lispro. RESEARCH DESIGN AND METHODS: Seven C-peptide-negative patients with type 1 diabetes (two men and five women) were studied at the General Clinical Research Center at Temple University Hospital two times, 1 month apart. Their plasma glucose was normalized overnight by intravenous infusion of insulin. The next morning, they received subcutaneous injections of either aspart or lispro (9.4 +/- 1.9 U) in random order. For the next 4-5 h, their plasma glucose was clamped at approximately 5.5 mmol/l with a variable infusion of 20% glucose. The study was terminated after 8 h. RESULTS: Both insulin analogs produced similar serum insulin levels (250-300 pmol/l) at approximately 30 min and disappeared from serum after approximately 4 h. Insulin aspart and lispro had similar effects on glucose and fat metabolism. Effects on carbohydrate metabolism (glucose uptake, glucose oxidation, and endogenous glucose production) peaked after approximately 2-3 h and disappeared after approximately 5-6 h. Effects on lipid metabolism (plasma free fatty acid, ketone body levels, and free fatty acid oxidation) appeared to peak earlier (at approximately 2 h) and disappeared earlier (after approximately 4 h) than the effects on carbohydrate metabolism. CONCLUSIONS: We conclude that both insulin aspart and lispro are indistinguishable from each other with respect to blood levels and that they are equally effective in correcting abnormalities in carbohydrate and fat metabolism in patients with type 1 diabetes. Continue reading >>
- Diet Soda Intake and Risk of Incident Metabolic Syndrome and Type 2 Diabetes in the Multi-Ethnic Study of Atherosclerosis (MESA)*
- CBD Oil And Diabetes - The Positive Effects Of CBD On Insulin And Metabolism
- Effects of resveratrol on glucose control and insulin sensitivity in subjects with type 2 diabetes: systematic review and meta-analysis
Humalog Vs Novolog (novalog): What's The Difference?
Humalog and Novolog are both rapid acting forms of insulin that work for short periods of time. Humalog Vs Novolog: Both human insulin analogs Humalog is a brand name for insulin lispro. Humalog starts to work about 15 minutes after injection, peaks in about 1 hour, and keeps working for 2 to 4 hours. Novolog is a brand name for insulin aspart. NovoLog starts to work about 15 minutes after injection, peaks in about 1 hour, and keeps working for 2 to 4 hours. Novolog is commonly misspelled as Novalog. Both medicines may be prescribed along with long-acting or intermediate-acting insulins. Humalog Vs Novolog: What exactly is the difference? Insulin consists of two polypeptide chains (A and B) linked together by disulfide bonds. Insulin lispro is human insulin that has been modified so that the amino acid proline has been substituted for lysine in position 28 of the B-chain, and lysine has been substituted for proline at position 29 of the B-chain. Insulin Aspart is human insulin that has a single substitution of proline for aspartic acid in position 28 of the B-chain. These seemingly minor substitutions significantly increase the rate of absorption of these insulin analogs into blood after subcutaneous injection. Peak concentrations are reached quicker than with regular human insulin, postprandial glucose control (level of blood sugars after a meal) is also improved, and there is less risk of late hypoglycemia (low blood sugar). Humalog Vs Novolog: Are there any differences in effect in people with diabetes? One small study concluded that there were no differences between Insulin lispro (Humalog) and Insulin Aspart (Novolog) in people with type 1 diabetes. Insulin levels in blood were similar 30 minutes after subcutaneous injection of either Lispro or Aspart and both disa Continue reading >>
Comparison Of Insulin Aspart And Lispro
Pharmacokinetic and metabolic effects Abstract OBJECTIVE—To compare insulin levels and actions in patients with type 1 diabetes after subcutaneous injection of the rapid-acting insulin analogs aspart and lispro. RESEARCH DESIGN AND METHODS—Seven C-peptide–negative patients with type 1 diabetes (two men and five women) were studied at the General Clinical Research Center at Temple University Hospital two times, 1 month apart. Their plasma glucose was normalized overnight by intravenous infusion of insulin. The next morning, they received subcutaneous injections of either aspart or lispro (9.4 ± 1.9 U) in random order. For the next 4–5 h, their plasma glucose was clamped at ∼5.5 mmol/l with a variable infusion of 20% glucose. The study was terminated after 8 h. RESULTS—Both insulin analogs produced similar serum insulin levels (250–300 pmol/l) at ∼30 min and disappeared from serum after ∼4 h. Insulin aspart and lispro had similar effects on glucose and fat metabolism. Effects on carbohydrate metabolism (glucose uptake, glucose oxidation, and endogenous glucose production) peaked after ∼2–3 h and disappeared after ∼5–6 h. Effects on lipid metabolism (plasma free fatty acid, ketone body levels, and free fatty acid oxidation) appeared to peak earlier (at ∼2 h) and disappeared earlier (after ∼4 h) than the effects on carbohydrate metabolism. CONCLUSIONS—We conclude that both insulin aspart and lispro are indistinguishable from each other with respect to blood levels and that they are equally effective in correcting abnormalities in carbohydrate and fat metabolism in patients with type 1 diabetes. Two rapidly acting insulin analogs, insulin lispro and aspart, are currently available in the U.S. and other countries for use in the management of d Continue reading >>
- Relative effectiveness of insulin pump treatment over multiple daily injections and structured education during flexible intensive insulin treatment for type 1 diabetes: cluster randomised trial (REPOSE)
- Insulin, glucagon and somatostatin stores in the pancreas of subjects with type-2 diabetes and their lean and obese non-diabetic controls
- Only 2 Ingredients and You Can Say Goodbye to Diabetes Forever! No More Medications and Insulin!!!
Switching From Novolog To Humalog
Looks like Ill be switching insulins, due to new Rx coverage, effective in January 2018. My endo has said they are essentially the same, but I thought Id check in here. Also on Lantus, but that will stay the same. Doing MDI with a CGM right now. I think there are minor differences that can be noticeable for some people. I tried Humalog briefly and found that I needed much more of it for carbs and corrections, that I had to increase my basal rates (I was using it in a pump) and that it didnt last as long. My son has not used Humalog, but Ive heard the same as @Scott_Eric . Calebs endo discourages its use bc of experience hes seen with pumping - it being more susceptible to clogging. Any chance your insurance is Aetna? We got a similar notice. I made that switch and didnt notice much of a differenceI think humalog may be a tiny bit faster/have less of a tail, but hard to say. Im also on MDI (humalog and tresiba, formerly lantus), so the clogging/pumping concern wasnt an issue. I used NovoLog for years and Ive used Humalog for years. I dont see any functional difference between the two. I have noticed on the internet some people claim they find difference between the two. If thats true its now a your mileage may vary issue Ive used both. I need about 12% more insulin on Humalog than on Novolog on MDI. But in a previous thread on a different message board, I noted that there were others who had the opposite experience. Also Humalog gets started a little faster than Novolog for me and at least in previous years had a slightly shorter tail. However, this year Ive noticed that a typical mealtime dose (8 units) of Humalog takes between five and six hours to finish working, which is as long as Novolog took the last time I was on it about three years ago.It may be just that at m Continue reading >>
Insulin Lispro - Injection, Humalog